A Phase I Study to Assess the Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With AS01B in Healthy UK Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs R 21 (Primary) ; AS01B
- Indications Malaria
- Focus Adverse reactions
- 19 Jun 2017 Status changed from recruiting to completed.
- 13 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.
- 13 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Mar 2017.